ERBB2 and breast cancer: In the present study, a set of analyses on a relatively small, though very well characterized, group of 106 non diabetic, HER2 positive breast cancer patients treated with trastuzumab confirmed our previous findings concerning the predictive role of pre-treatment fasting glucose on treatment outcomes.